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Abstract
Background: The relationship between medication non-compliance in patients with schizophrenia and related
disorders, and increased psychiatric service utilization and costs are well documented; however, non-psychiatric
service utilization and costs are not. Therefore, we investigated the association of non-compliance with psychiatric
treatment and the utilization and costs of non-psychiatric services.
Methods: Data on South Korean individuals with a lifetime diagnosis of schizophrenia or a related disorder, who
were treated in a psychiatric clinic at least twice during 2011, were selected among national data collected for the
Health Insurance Review and Assessment Service-National Patients Sample between January 1, 2011 and December
31, 2011. The sample was divided into two overlapping groups with two different classifications of patterns of
medication prescription refills: (1) adherent versus non-adherent group, and (2) persistent versus non-persistent
group. A matching method was used to remove the effects of different follow-up durations and insurance system
on medical service utilization and costs. The final sample for analysis consisted of data from 5,548 individuals in the
adherent versus non-adherent group and 3,912 in the persistent versus non-persistent group. Comparisons of the
psychiatric and non-psychiatric service utilizations were made between the groups.
Results: The number of psychiatric service utilizations were significantly lower in the non-adherent than the
adherent group. They were also significantly lower in the non-persistent group than the persistent group. The
number of non-psychiatric service utilizations was significantly higher in the non-adherent group. They were also
significantly higher in the non-persistent group than the persistent group. All psychiatric costs per person during
the study period were lower in the non-adherent than the adherent group, and lower in the non-persistent than
the persistent group. All non-psychiatric costs per person were higher in the non-adherent than the adherent
group, and higher in the non-persistent than the persistent group.
Conclusion: Non-adherence to psychiatric treatment by patients with schizophrenia and related disorders was
associated with higher medical service utilization and increased personal and societal medical costs.
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Background
Poor medication adherence is common among patients
with schizophrenia, and is associated with higher health-
care resource utilization and costs [1–5]. Medication
non-compliance, which is related to poor psychosocial
functioning [6–8], poor self-care, and an unhealthy life-
style, increases the probability of medical service
utilization and costs. It also may negatively affect non-
psychiatric service utilization and costs. Although
research has examined the association of medication
non-compliance with healthcare service utilization and
costs [3, 6, 9–12], most studies have focused on psychi-
atric services, such as psychiatric hospitalization and
community day-programs. Little attention has been
given to non-psychiatric service utilization and costs.
The relationship between non-compliance and the use
of psychiatric services varies across types of services [5,
10, 13, 14]. For instance, non-compliance is associated
with the use of medical clinic services [15], which might
be because non-compliant patients exhibit fewer help-
seeking behaviors. Whether non-compliance with psy-
chiatric medications by patients with schizophrenia
affects non-psychiatric service utilization and costs has
not been investigated. Therefore, the impact of psychi-
atric medication compliance on non-psychiatric service
utilization and costs should be evaluated.
A previous study on psychiatric and non-psychiatric
service utilization comparing patients continuing anti-
psychotics and patients discontinuing them [15], found
that the patients continuing antipsychotics had higher
rates of emergency-room use, out-patient hospitaliza-
tions, and other out-patient services for both psychiatric
and non-psychiatric reasons. However, the study did not
investigate the association of adherence (i.e., the extent
to which the patient took the medication as prescribed)
with psychiatric and non-psychiatric service utilization.
In addition, previous studies have not measured the
costs of psychiatric and non-psychiatric service
utilization. A study of the impact of compliance with
psychiatric and non-psychiatric service use, using sys-
tematic measures of compliance and healthcare costs,
was needed. Hence, this study investigated the associa-
tions between psychiatric medication non-compliance
and psychiatric and non-psychiatric service utilization
and costs separately, using two dimensions of compli-
ance: adherence and persistence.
Methods
Data characteristics
This study analyzed data from the Health Insurance Re-
view and Assessment Service-National Patients Sample
(HIRA-NPS) between January 1, 2011 and December 31,
2011 (NPS-2011-0101). The HIRA-NPS is a stratified,
random sample from a South Korean health insurance
review database. Detailed information about the HIRA-
NPS is provided in Additional file 1. As this information
is public data and was unlinked to personal identifiers,
informed consent was not necessary and unobtainable.
This study was approved by the institutional review
board of Ulsan University Hospital (IRB File No: 2015-
10-020) with which the first author is affiliated.
Selection of patient data
The patient selection process is illustrated in Additional
file 2. Patients who met the following criterion were in-
cluded: a diagnosis of schizophrenia or related disorder
as defined by the 6th revision of the Korean Standard
Classification of Diseases [16], which is a modification of
the International Classification of Diseases-10 [17]. Pa-
tients who met the following criteria were excluded: (a)
a diagnosis of schizophrenia or related disorder treated
only in a non-psychiatric clinic (e.g., oriental medicine
or public health) during the follow-up period and (b) pa-
tients with follow-up periods that were too short to
measure compliance (i.e., the first visit was during the
follow-up period, but the second one was scheduled
after the follow-up period).
Psychiatric medications
The psychiatric medications identified as those used by
the patients in our sample included: (1) antipsychotics:
amisulpride, aripiprazole, haloperidol, clozapine, olanza-
pine, paliperidone, risperidone, quetiapine, ziprasidone,
chlorpromazine, sulpiride, zotepine, blonanserin, pimo-
zide; (2) mood stabilizers: lithium, valproate, carbamaze-
pine, lamotrigine; (3) antidepressants: amitriptyline,
imipramine, tianeptine, mirtazapine, trazodone, escitalo-
pram, fluoxetine, fluvoxamine, paroxetine, sertraline,
duloxetine, milnacipran, velnafaxine, moclobemide, nal-
trexone, acamprosate, bupropion, nortryptiline, clomip-
ramine; (4) anti-anxiety drugs: diazepam, clorazepam,
chlordiazepoxide, buspirone, alprazolam, flunitrazepam,
clonazepam, clobazam and (5) sleeping pills: zolpidem.
Only the oral form of the medication was used to meas-
ure compliance because compliance with depot medica-
tion is distinct from the oral medication and the
proportion of unopposed usage of depot form is smaller
than the oral form.
Compliance measures
We measured two dimensions of compliance and classi-
fied the patients into the two dimensions: adherence and
persistence [18]. Adherence usually refers to the extent
to which a patient takes medicine as prescribed, whereas
persistence refers to the continuation with the medication
as prescribed. This differentiation is clinically meaningful
because non-adherent behavior and non-persistent behav-
ior may have different social and psychological causes,
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which can be solved by different intervention strategies
[19]. Many non-persistent patients may be non-adherent
at the same time. However, the dimensions are not the
exactly same. Non-adherent patients are not always non-
persistent and vice versa.
In this study, we defined adherence as the extent to
which a patient was prescribed psychiatric medication
between the first psychiatric visit and the last psychiatric
visit during 2011. Duration of follow-up was defined as
number of days between the first psychiatric visit and
the last psychiatric visit during 2011. We excluded the
last prescription because the patients might not have
taken their last prescribed medicine when they were lost
to follow-up, and because the last prescription might
have been finished after the end of the follow-up period.
Persistence in this study was defined as whether a psy-
chiatric prescription was interrupted during the follow-
up period.
Adherence patterns
Adherence to psychiatric treatment was evaluated by
calculating the percentage of days of psychiatric pre-
scription (PDP): PDP = (Total days of the psychiatric
prescription - Number of prescription days to the last
day of the prescription - Total days of overlapping pre-
scription (s) due to a premature visit)/(Duration of fol-
low up, i.e., number of days between the first psychiatric
visit and the last psychiatric visit). We defined adherence
as a PDP ≥ 80% and non-adherence as a PDP < 80%.
Persistence patterns
The interruption of continuous psychiatric medication
was defined as having a refill gap of 8 weeks or longer
and a re-initiation of medication during the follow-up
period. Patients with at least one or more interruptions
were classified as non-persistent, and patients without
an interruption were classified as persistent.
Matching procedure
Data for the final analysis were obtained by matching
the duration of follow up and the distribution of the
types of insurance between the adherent and non-
adherent groups, and between the persistent and non-
persistent groups. A total of 7,848 patients met the
inclusion criteria. The mean duration of follow up was
319.97 days (SD = 72.98) and the mean duration of psy-
chiatric prescriptions was 213.23 days (SD = 130.26). We
divided the total sample into adherent and non-adherent
groups, and matched the duration of follow up and insur-
ance type between the groups using a propensity-score
matching method. Each of the 2,774 non-adherent pa-
tients was matched with a patient in the corresponding
group. We also divided the total sample into a persistent
group, in which patients continued their medication
(medication without interruption ≤ 56 days) and a non-
persistent group, in which patients discontinued their
medication at least once (medication with interruption >
56 days), and matched the duration of follow-up and
insurance type of these two groups. Each of the 1,956
non-persistent patients was matched with a patient in the
corresponding group. We identified 1,041 patients who
were both non-adherent and non-persistent in the non-
adherent and non-persistent groups. In the non-persistent
group, 915 patients (62.5%) were non-persistent but ad-
herent; and in the non-adherent group, 1,733 patients
were non-adherent (46.8%) but persistent.
Medical service utilizations and costs
The number of visits to psychiatric clinics, number of
psychiatric hospitalizations, duration of psychiatric hos-
pitalizations, duration of psychiatric medications, num-
ber of visits to medical clinics, number of medical
hospitalizations, duration of medical hospitalizations,
duration of psychiatric medications, number of emer-
gency room visits, number of deaths in the follow-up
period, number of surgeries, and the medical costs dur-
ing the year 2011, were investigated.
Statistical analyses
All statistical analyses were conducted using the STATA
(Version 13, STATA Corp, LP) statistical package. Group
comparisons were made with chi-square tests for cat-
egorical variables and Student’s t-tests for continuous
variables. Poisson regression, multiple regression, and lo-
gistic regression analysis, adjusted for sex, age, and
follow-up duration were used to determine the associ-
ation between non-compliance (non-adherent and non-
persistent) and the frequency of using various healthcare
services and mortality. The original data did not provide
information about the severity of illness of the individ-
uals in the sample. Therefore, we used the average daily
chlorpromazine equivalent dose of antipsychotics as an
indirect measure to control for the severity of illness.
We assumed that the prescription of a higher anti-
psychotic dose would reflect a greater severity of mental
illness. The daily chlorpromazine equivalent dose of an-
tipsychotics was calculated using several published
equivalencies for antipsychotics [20–24].
Results
Demographic and clinical characteristics
The mean age of the 5,548 patients in the adherent and
non-adherent groups was 48.28 years (SD = 16.91) and that
of the 3,912 patients in the persistent and non-persistent
groups was 49.87 years (SD = 18.73). Schizophrenia was
the most common diagnosis (75.34 and 69.81%) for the
adherence/non-adherence and persistent/non-persistent
classifications, respectively). The mean duration of follow
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up was 332.54 days (SD = 58.17) for the adherence/non-ad-
herence classification and 316.98 days (SD = 68.45) for the
persistent/non-persistent classification. The mean duration
of psychiatric medication treatment was 218.62 days (SD =
125.93) for the adherence/non-adherence classification and
158.12 days (SD = 132.84) for the persistent/non-persistent
classification.
There was no statistically significant difference in gender
between the adherent and non-adherent groups (p =
0.7680) or the persistent and non-persistent groups (p =
0.8230). However, the mean age was significantly higher
(p < 0.001) in the non-adherent (50.71, [SD = 18.58]) than
the adherent group (45.85, [SD = 14.66], p < 0.001) and in
the non-persistent (54.16, [SD = 20.67]) than the persistent
group (45.59, [SD = 15.42]). The distribution of diagnoses
was significantly different between the adherent and non-
adherent groups and the persistent and non-persistent
groups. The proportion of diagnoses of schizophrenia
among all diagnoses of schizophrenia and related disor-
ders was larger in the adherent group (79.2%) than the
non-adherent group (71.5%). The proportion of diagnoses
of schizophrenia among all diagnoses of schizophrenia
and related disorders was larger in the persistent group
(74.3%) than the non-persistent group (65.3%). The
matching procedure eliminated potential differences in
follow-up duration and insurance type between the
groups. The mean duration of psychiatric medications was
significantly lower in the non-adherent (133.77, [SD =
117.53]) than the adherent group (303.48, [SD = 59.21])
and lower in the non-persistent (51.22, [SD = 73.83]) than
the persistent group (265.02, [SD = 83.56]).
Adjusted influence of non-compliance (non-adherence
and non-persistence) on psychiatric and non-psychiatric
service utilization
Table 1 presents the utilization of psychiatric and
non-psychiatric services by compliance (adherence
and persistence) pattern. With respect to the influ-
ence of non-adherence (versus adherence) on the
utilization of psychiatric services, the total number of
visits to psychiatric clinics was significantly lower in the
non-adherent group by 0.469 (95% CI: −0.487–0.450, p <
0.001). The total number of psychiatric hospitalizations
was significantly lower in the non-adherent group by
0.049 (95% CI: −0.086–-0.012, p = 0.009). The total dur-
ation of psychiatric hospitalizations was not significant (p
= 0.309), and the duration of psychiatric medications was
significantly lower in the non-adherent group by
138.05 days (95% CI: −142.893–-133.210, p < 0.001).
The number of visits to medical clinics significantly
increased by 0.354 (95% CI: 0.325–0.384, p < 0.0001), the
number of medical hospitalizations significantly increased










Mean SD Mean SD Mean SD Mean SD
Psychiatric-related service utilization
Total number of visits to psychiatric clinics1) 6.51 6.38 10.89 8.30 −0.469 <0.001 5.03 5.85 10.14 7.84 −4.543 <0.001
Total number of psychiatric
hospitalizations1)
2.02 3.95 2.15 4.42 −0.049 0.009 0.97 2.57 1.76 3.86 −0.749 <0.001
Total duration of psychiatric
hospitalizations2) (days)
56.60 202.61 63.61 209.34 −5.592 0.309 24.34 69.94 57.81 305.52 −32.438 <0.001
Total duration of psychiatric medications2)
(days)
210.42 131.03 354.41 66.26 −138.052 <0.001 146.36 136.95 314.34 95.96 −166.17 <0.001
Non-psychiatric related service utilization
Total number of visits to medical clinics1) 4.62 7.34 2.62 6.98 0.354 <0.001 6.02 8.17 3.21 7.08 2.132 <0.001
Total number of medical hospitalizations1) 1.04 2.59 0.26 1.25 1.136 <0.001 1.34 2.81 0.36 1.36 0.760 <0.001
Total duration of medical hospitalization2)
(days)
50.08 433.04 5.63 31.59 39.530 <0.001 72.70 587.91 13.82 209.13 47.869 0.001
Total duration of medical medications2)
(days)
131.75 178.52 64.87 147.37 50.437 <0.001 174.92 190.56 81.50 162.69 66.652 <0.001
Total number of emergency room visits1) 0.31 1.30 0.14 1.08 0.737 <0.001 0.32 1.04 0.17 1.04 0.106 0.002
Total number of surgeries1) 0.13 0.48 0.02 0.17 1.442 <0.001 0.19 0.59 0.04 0.25 0.115 <0.001
OR P OR P
Number of deaths during the follow-up
period3)
0.03 0.17 0.02 0.14 1.199 0.324 0.03 0.18 0.01 0.11 1.950 0.007
**p < 0.001; adherence is defined as the percentage of days of psychiatric prescription (PDP) ≥ 80% and non-adherence as a PDP < 80%; participants consisted of
patients with schizophrenia and related disorders; 1) results were obtained by Poisson regression analysis with the general linear model; 2) results were obtained
by multiple linear regression analysis; and 3) results were obtained by logistic regression analysis
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by 1.136 (95% CI: 1.052–1.220, p < 0.001), and the dur-
ation of medical hospitalizations significantly increased by
39.53 days (95% CI: 23.199–55.861, p < 0.001) in the non-
adherent group. In addition, the total duration of medical
medication significantly increased by 50.44 days (95% CI:
42.447–58.427, p < 0.001), the number of emergency room
visits significantly increased by 0.737 (95% CI: 0.615–
0.859, p < 0.0001), and the number of surgeries signifi-
cantly increased by 1.442 (95% CI: 1.172–1.711, p <
0.0001,) in the non-adherent group. The mortality rate
was not significantly (p = 0.324) different between non-
adherent and adherent group.
The results of the influence of non-persistence (versus
persistence) on the utilization of psychiatric services
showed that the total number of visits to psychiatric
clinics was significantly lower by 4.543 (95% CI: −4.966–
4.121, p < 0.001) and the number of psychiatric hospitali-
zations was significantly lower by 0.749 (95% CI: −0.953–
0.545, p < 0.001) in the non-persistent group. The total
duration of psychiatric hospitalizations was significantly
lower by 32.44 days (95% CI: −46.661–-18.214, p < 0.001)
and the duration of psychiatric medications was signifi-
cantly lower by 160.17 days (95% CI: −166.650–-153.693,
p < 0.0001) in the non-persistent group.
Non-persistence influenced the utilization of non-
psychiatric services, significantly increasing the total
number of visits to medical clinics by 2.132 (95% CI:
1.657–2.606, p < 0.0001), the number of medical hospi-
talizations by 0.760 (95% CI: 0.622–0.898, p < 0.0001),
and duration of medical hospitalizations by 47.87 days
(95% CI: 19.420–76.317, p < 0.001) in the non-persistent
group. Non-persistence significantly increased the total
duration of medical medications by 66.65 days (95% CI
56.374–76.930, p < 0.0001), the number of emergency
room visits by 0.106 (95% CI: 0.039–0.172, p < 0.002),
and the number of surgeries by 0.115 (95% CI: 0.086–
0.144, p < 0.0001) in the non-persistent group. The mor-
tality rate was significantly higher in the non-persistent
than the persistent group (OR, 1.950, 95% CI: 1.195–
3.181, p < 0.007).
Adjusted influence of non-compliance (non-adherence
and non-persistence) on psychiatric and non-psychiatric
costs
Table 2 presents the yearly medical service costs per per-
son with schizophrenia and related disorders (1,000 Ko-
rean Won was equivalent to 1.1–1.2 US dollars in 2011).
After adjusting for the covariates i.e., sex, age, duration
of follow-up, and insurance type (national health insur-
ance or others), all of the associations between the com-
pliance patterns and non-psychiatric costs were
statistically significant. The total psychiatric costs were
significantly lower by 783,300 won (p < 0.001) in the
non-adherent group. Psychiatric copayments and gov-
ernment payments were also lower by 74,800 and 70,500
won respectively (p ≤ 0.001), in the non-adherent group.
The total non-psychiatric costs were significantly higher
by 1,401,300 won (p < 0.001) in the non-adherent group.
Non-psychiatric copayments and government payments
were also higher by 163,900 and 1,219,700 won respect-
ively (p < 0.001), in the non-adherent group. The com-
bined psychiatric and non-psychiatric total costs were
higher by 618,000 won in the non-adherent group (p =
0.001). The combined psychiatric and non-psychiatric
copayments and the government payments were also










Mean SD Mean SD Mean SD Mean SD
Psychiatric-related costs
Total costs 3061 5101 3907 5954 −783.3 <0.001 1553 3170 3317 5341 −974.8 <0.001
Copayments 343 826 420 973 −74.8 0.001 251 617 445 938 −69.4 <0.001
Government payments 2697 4585 3463 5307 −705.0 <0.001 1293 2759 2845 4632 −897.7 <0.001
Non-psychiatric related
Total costs 1900 6527 211 1450 1401.3 <0.001 3039 8532 327 1673 1614.1 <0.001
Copayments 243 988 28 259 163.9 <0.001 397 1238 52 291 200.1 <0.001
Government payments 1628 5715 181 1220 1219.7 <0.001 2605 7538 266 1373 1403.0 <0.001
Total psychiatric and non-psychiatric-related costs
Total costs 4961 7867 4118 6109 617.996 0.0010 4592 8803 3644 5626 639.302 0.0100
Copayments 586 1261 448 1009 89.090 0.0020 648 1355 497 1003 717.831 0.0010
Government payments 4324 7004 3644 5434 514.649 0.0020 3899 7801 3112 4863 505.311 0.0190
**p < 0.001; adherence is defined as the percentage of days of psychiatric prescription (PDP) ≥ 80% and non-adherence as a PDP < 80%; currency unit = 1,000
Korean Won; data were collected from patients with schizophrenia and related disorders; the covariates included sex, age, duration of follow up, and insurance
type (national health insurance or another type)
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higher by 89,100 and 514,600 won respectively, in the
non-adherent group.
The total psychiatric costs were significantly lower by
974,800 won (p = 0.001) in the non-persistent group.
The psychiatric copayments and government payments
were also lower by 69,400 and 897,700 won respectively
(p < 0.01), in the non-persistent group. The total non-
psychiatric costs were significantly higher by 1614,100
won (p < 0.001) in the non-persistent group. The non-
psychiatric copayments and government payments were
also higher by 200,100 and 1403,000 won respectively (p
< 0.001), in the non-persistent group. The combined
psychiatric and non-psychiatric total costs were higher
by 639,302 won in the non-persistent group (p = 0.01).
The combined psychiatric and non-psychiatric copay-
ments and government payments were also higher by
717,831 and 505,311 won respectively (p < 0.05), in the
non-persistent group.
Discussion
This is the first study to compare psychiatric and non-
psychiatric service utilization and costs between groups
by evaluating two different compliance patterns. It is
also the first study to investigate compliance, medical
service utilization, and personal and societal costs
among patients with schizophrenia and related disorders
from a nationwide survey of an East Asian country.
The lower service utilization (i.e., psychiatric visits and
total prescriptions) by patients who were non-compliant
in this study might be a direct result of lower compli-
ance itself because non-compliant patients tend to avoid
using healthcare services. However, the duration of
psychiatric hospitalization was not significantly different
between the non-adherent and the adherent groups.
This might be due to the higher relapse frequency in the
non-adherent group, also documented in other studies
[1, 2, 25]. In those studies, non-adherent patients tended
to refuse hospitalization although frequent exacerbations
of psychosis increased the likelihood of hospitalization.
In this study, the higher number of relapses and hospi-
talizations might have compensated for the lower service
utilization associated with non-adherence. The shorter
duration of hospitalization of non-persistent patients
might be related to the shorter duration of the follow-up
period. Long-term follow-up might have led to shorter
hospitalizations of the non-adherent than the adherent
group. Another possibility is that the length of
hospitalization might be more variable for those with
the adherence rather than the persistence pattern. Non-
persistent behavior, characterized by interruptions in
treatment, might have a stronger relationship with pre-
mature discharge than non-adherent behavior.
In contrast, medical service utilization was higher in
the non-compliant groups, suggesting that it was related
to a higher number of medical comorbidities. Medical
comorbidities among patients visiting psychiatric clinics
have been estimated at 43–47% [26–28], and found to
be responsible for 60% of premature deaths in patients
with schizophrenia, excluding suicide [29].
These findings might be related to higher rates of
unhealthy lifestyle behaviors, such as smoking, excessive
alcohol consumption, and poor self-care habits (e.g., hy-
giene, diet, and exercise) in patients with schizophrenia
[4]. Patients with schizophrenia receive little medical at-
tention from physicians [30], and therefore, may have
fewer medical visits and documented medical problems.
Thus, higher medical service utilization in non-
compliant patients suggests that non-compliance might
be associated with medical comorbidities that are more
severe. Unhealthy lifestyle habits in patients with a se-
vere mental illness, who are non-compliant, may result
in poor physical health and higher utilization of medical
services. Non-compliance might be another indicator of
the illness’ severity and result in higher mortality and
medical morbidity.
Our results suggest that non-compliance was related
to higher health service costs and may be related to
higher medical service utilization by non-compliant pa-
tients. Despite lower psychiatric service utilization by
the non-compliant patients, their total healthcare costs
were higher than those in the compliant group, suggest-
ing that non-compliance with psychiatric prescriptions
influenced total healthcare costs by increasing medical
healthcare costs. Increased medical costs were suffi-
ciently higher to reverse the effect of the decrease in
psychiatric costs of the non-compliant group. Both per-
sonal and governmental burdens, as measured by the
medical and total health care costs were higher in the
non-compliant group. Thus, there is a pressing need to
treat patients with schizophrenia and related disorders
and for government to support this effort. Increasing the
compliance of patients with these diagnoses may directly
reduce the national economic burden.
Among the compliance dimensions, persistence had a
strong association with increased utilization of non-
psychiatric services. This suggests that the discontinu-
ation of psychiatric treatment or a long interval between
psychiatric treatments might play a more significant role
in maintaining the medical health of this patient popula-
tion than the percentage of medications taken during
the follow-up period. Alternatively, persistence rather
than adherence might have a greater influence on med-
ical service utilization. Therefore, non-persistent patients
might be more non-compliant than non-adherent
patients, and they might be more likely to neglect the
self-care activities needed to stay healthy. Both of the
compliance dimensions had similar influences on med-
ical service costs, indicating that unhealthy behaviors
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had a similar influence on the economic aspects of
healthcare utilization. The differences in cost per visit
between the non-persistent and persistent patients may
be greater than that between the non-adherent and ad-
herent patients.
This study has several limitations, all of them related
to the limitations of the original data. First, the follow-up
period was relatively short. One year was the maximum
follow-up period because new samples for the national
data set are selected yearly. Second, the original data did
not include information about additional out-of-pocket
payments by patients. Although budgeting for out of
pocket payments is strictly limited by the South Korean
government, one should remember that actual healthcare
service costs are larger than those cited in this study are.
Third, the analyses of data from this sample might not be
representative because the participants were selected from
a subset of patients with schizophrenia and related disor-
ders, and matched on their insurance type and availability
for the follow-up period. Fourth, baseline psychiatric
characteristics, such as age at onset, duration of
illness, previous number of hospitalizations, and dur-
ation of psychiatric treatment were not analyzed be-
cause past psychiatric history was not available in the
original data. Therefore, the baseline data of the sam-
ple were not the same although the representativeness
of the national sample and the adequate sample size
might compensate for this limitation.
Conclusion
Non-compliance of psychiatric treatment in persons
with schizophrenia and related disorders is associated
with higher medical service utilization and increased
medical costs.
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